Vimian Group Valuation
Is VIMIAN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of VIMIAN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: VIMIAN (SEK42.8) is trading below our estimate of fair value (SEK56.6)
Significantly Below Fair Value: VIMIAN is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VIMIAN?
Other financial metrics that can be useful for relative valuation.
What is VIMIAN's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | €1.96b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 6.1x |
Enterprise Value/EBITDA | 30.6x |
PEG Ratio | 3.1x |
Price to Sales Ratio vs Peers
How does VIMIAN's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 9.3x | ||
XVIVO Xvivo Perfusion | 22.8x | 27.4% | SEK 15.9b |
BACTI B Bactiguard Holding | 7.5x | 9.7% | SEK 1.6b |
OSSD OssDsign | 5.3x | 23.9% | SEK 654.3m |
EKTA B Elekta | 1.5x | 6.0% | SEK 27.3b |
VIMIAN Vimian Group | 5.7x | 13.6% | SEK 22.4b |
Price-To-Sales vs Peers: VIMIAN is good value based on its Price-To-Sales Ratio (5.7x) compared to the peer average (9.3x).
Price to Earnings Ratio vs Industry
How does VIMIAN's PE Ratio compare vs other companies in the SE Medical Equipment Industry?
Price-To-Sales vs Industry: VIMIAN is expensive based on its Price-To-Sales Ratio (5.7x) compared to the Swedish Medical Equipment industry average (4.6x).
Price to Sales Ratio vs Fair Ratio
What is VIMIAN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 5.7x |
Fair PS Ratio | 6.9x |
Price-To-Sales vs Fair Ratio: VIMIAN is good value based on its Price-To-Sales Ratio (5.7x) compared to the estimated Fair Price-To-Sales Ratio (6.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | SEK 42.80 | SEK 44.73 +4.5% | 23.1% | SEK 55.73 | SEK 28.13 | n/a | 7 |
Oct ’25 | SEK 45.95 | SEK 43.98 -4.3% | 22.9% | SEK 55.01 | SEK 27.76 | n/a | 7 |
Sep ’25 | SEK 42.85 | SEK 41.06 -4.2% | 20.0% | SEK 51.02 | SEK 27.53 | n/a | 7 |
Aug ’25 | SEK 33.70 | SEK 40.52 +20.2% | 17.3% | SEK 50.50 | SEK 28.47 | n/a | 7 |
Jul ’25 | SEK 33.80 | SEK 38.03 +12.5% | 17.6% | SEK 47.96 | SEK 27.30 | n/a | 7 |
Jun ’25 | SEK 34.95 | SEK 39.12 +11.9% | 18.8% | SEK 50.47 | SEK 27.92 | n/a | 7 |
May ’25 | SEK 30.30 | SEK 39.36 +29.9% | 22.5% | SEK 51.52 | SEK 27.13 | n/a | 6 |
Apr ’25 | SEK 32.50 | SEK 38.69 +19.0% | 22.5% | SEK 50.36 | SEK 27.01 | n/a | 6 |
Mar ’25 | SEK 30.24 | SEK 39.01 +29.0% | 20.8% | SEK 49.97 | SEK 27.84 | n/a | 7 |
Feb ’25 | SEK 28.68 | SEK 37.55 +30.9% | 18.8% | SEK 48.91 | SEK 28.20 | n/a | 7 |
Jan ’25 | SEK 29.60 | SEK 37.01 +25.0% | 18.8% | SEK 47.99 | SEK 27.67 | n/a | 7 |
Dec ’24 | SEK 26.28 | SEK 38.05 +44.8% | 20.3% | SEK 48.86 | SEK 27.33 | n/a | 6 |
Nov ’24 | SEK 26.02 | SEK 42.67 +64.0% | 16.8% | SEK 49.92 | SEK 28.43 | n/a | 6 |
Oct ’24 | SEK 23.84 | SEK 44.34 +86.0% | 9.9% | SEK 49.95 | SEK 36.97 | SEK 45.95 | 6 |
Sep ’24 | SEK 33.08 | SEK 44.20 +33.6% | 9.9% | SEK 49.78 | SEK 36.84 | SEK 42.85 | 6 |
Aug ’24 | SEK 27.26 | SEK 43.78 +60.6% | 9.1% | SEK 50.99 | SEK 38.12 | SEK 33.70 | 6 |
Jul ’24 | SEK 25.60 | SEK 44.76 +74.8% | 9.0% | SEK 51.82 | SEK 38.74 | SEK 33.80 | 6 |
Jun ’24 | SEK 30.76 | SEK 43.94 +42.8% | 9.5% | SEK 49.93 | SEK 37.33 | SEK 34.95 | 6 |
May ’24 | SEK 37.18 | SEK 41.31 +11.1% | 12.3% | SEK 49.86 | SEK 33.52 | SEK 30.30 | 6 |
Apr ’24 | SEK 32.78 | SEK 41.17 +25.6% | 12.4% | SEK 49.57 | SEK 33.32 | SEK 32.50 | 6 |
Mar ’24 | SEK 23.32 | SEK 46.55 +99.6% | 21.5% | SEK 61.90 | SEK 34.87 | SEK 30.24 | 6 |
Feb ’24 | SEK 29.14 | SEK 48.27 +65.6% | 20.2% | SEK 61.87 | SEK 36.09 | SEK 28.68 | 6 |
Jan ’24 | SEK 27.22 | SEK 47.31 +73.8% | 20.0% | SEK 59.64 | SEK 34.78 | SEK 29.60 | 6 |
Dec ’23 | SEK 36.76 | SEK 47.31 +28.7% | 20.0% | SEK 59.64 | SEK 34.78 | SEK 26.28 | 6 |
Nov ’23 | SEK 33.92 | SEK 62.85 +85.3% | 30.8% | SEK 85.78 | SEK 29.97 | SEK 26.02 | 5 |
Oct ’23 | SEK 26.36 | SEK 66.70 +153.0% | 25.5% | SEK 84.95 | SEK 35.08 | SEK 23.84 | 5 |
Analyst Forecast: Target price is less than 20% higher than the current share price.